Pacira BioSciences, Inc.
PCRX
$22.65
-$0.05-0.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.63% | 3.14% | 2.25% | 3.08% | 3.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.63% | 3.14% | 2.25% | 3.08% | 3.85% |
| Cost of Revenue | 2.84% | -7.56% | -9.67% | -9.87% | -10.94% |
| Gross Profit | 3.99% | 8.12% | 7.94% | 9.54% | 12.21% |
| SG&A Expenses | 25.39% | 23.72% | 20.23% | 14.12% | 9.15% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.78% | 10.83% | 8.19% | 4.11% | 2.68% |
| Operating Income | -71.51% | -41.53% | -32.32% | -3.36% | 11.74% |
| Income Before Tax | 126.74% | 176.17% | -205.97% | -166.83% | -202.28% |
| Income Tax Expenses | -73.01% | -43.07% | -43.42% | 13.85% | 84.61% |
| Earnings from Continuing Operations | 107.07% | 123.63% | -300.43% | -247.19% | -337.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 107.07% | 123.63% | -300.43% | -247.19% | -337.30% |
| EBIT | -71.51% | -41.53% | -32.32% | -3.36% | 11.74% |
| EBITDA | -32.62% | -18.52% | -9.64% | 2.38% | 8.26% |
| EPS Basic | 107.37% | 123.74% | -301.59% | -247.83% | -339.16% |
| Normalized Basic EPS | -77.33% | -44.85% | -38.89% | 4.63% | 28.47% |
| EPS Diluted | 106.76% | 122.13% | -307.43% | -255.74% | -359.04% |
| Normalized Diluted EPS | -76.01% | -42.25% | -33.99% | 11.89% | 34.86% |
| Average Basic Shares Outstanding | -3.63% | -1.78% | -0.80% | -0.37% | 0.05% |
| Average Diluted Shares Outstanding | -9.34% | -7.69% | -9.53% | -7.75% | -2.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |